PARP1 and neoplasm of testis: These observations might have clinical relevance as currently, two phase II clinical trials are evaluating the potential of PARP inhibition in relapsed or refractory testicular tumours, either as single agent (NCT02533765) or combined with gemcitabine and carboplatin (NCT02860819).